Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLL
Looking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.
Pirtobrutinib and Other Non-Covalent BTK Inhibitors in the Treatment of CLL
The assembled faculty comment on data on the role of non-covalent BTK inhibitors in the CLL treatment landscape, with emphasis on the phase 1/2 BRUIN trial of pirtobrutinib.
Anti-CD20 Regimens and Triplet Therapies in CLL
Orienting the conversation around anti-CD20-drug-based combination and sequencing approaches, the panelists examine key takeaways from the CLL13 and CLL14 clinical trials as well as expectations for real-world data in the future.
Considerations for COVID-19 in MCL and CLL
Focusing the discussion on the current state of the COVID-19 pandemic, Catherine C. Coombs, MD, shares key insights into the use of COVID-19 pre-exposure prevention for patients with CLL or MCL.
The Potential Role of Venetoclax Combination Approaches in CLL
Experts in hematologic malignancies reflect on clinical trials studying venetoclax combination approaches including the CAPTIVATE, FLAIR, GLOW, VISION, SEQUOIA, and MAJIC studies.
TRANSCEND CLL: CAR T-cell Therapy for CLL
Panelists respond to a question from Michael Wang, MD, about the role of CAR T-cell therapy in CLL, and Brian T. Hill, MD, PhD, summarizes takeaways from the TRANSCEND CLL study.
Emerging Approaches in CLL
The faculty members share expert insights into treatment approaches for patients with double-refractory chronic lymphocytic leukemia.
Updates from Patient-reported QOL and Matching-adjusted Indirect Treatment Comparisons (MAICs) Studies in CLL
Brian T. Hill, MD, PhD, and Matthew S. Davids, MD, MMSc, address the role of study design in CLL to highlight the importance of patient-reported QOL outcomes and matching-adjusted indirect treatment comparisons (MAICs).
Treatment Decision-making Among Second-generation BTKis in CLL
Key opinion leaders in CLL review factors driving therapeutic decision-making among the available second-generation BTK inhibitors including efficacy and safety considerations.
Zanubrutinib in CLL: The ALPINE Trial
An expert in hematologic malignancies, Catherine C. Coombs, MD, shares insights gleaned from the ALPINE clinical trial of zanubrutinib vs ibrutinib for relapsed/refractory CLL.
Acalabrutinib in CLL: Insights from the ELEVATE TN and ASCEND Trials
Highlighting the ELEVATE TN and ASCEND clinical trials, panelists share expert insights into the next-generation BTK inhibitor acalabrutinib for CLL.
Treatment Overview: Chronic Lymphocytic Leukemia
Catherine C. Coombs, MD, leads the faculty in a discussion of the current treatment landscape for CLL with a review of considerations for patients with high-risk or relapsed/refractory disease.
Advancements on the Horizon in Mantle Cell Lymphoma
Thought leaders in hematologic malignancies reflect on studies of ROR1 and share perspectives on advancements on the horizon for mantle cell lymphoma.
Strategies for Sequencing and Combining Therapies in MCL
A panel of distinguished faculty builds a lively conversation on the emergence of pirtobrutinib and its effect on treatment sequencing strategies in MCL as well as the overall role of doublet and triplet regimens.
CAR T-Cell Therapy in R/R MCL
Michael Wang, MD, guides the panel in a discussion on CAR T-cell therapy for relapsed/refractory MCL including a summary of key takeaways from the ZUMA-2 trial and a conversation on real-world vs clinical trial data.
BTK Inhibitors in Relapsed/Refractory MCL and Treatment Selection
Panelists discuss treatment considerations in the use of BTK inhibitors for relapsed/refractory mantle cell lymphoma, with Matthew S. Davids, MD, MMSc, reviewing strategies for the management of AEs.
Second-line Therapies in MCL: Regimens With BTK Inhibitors and BCL-2 Targeting Therapies
Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.
Mantle Cell Lymphoma Maintenance Strategies
A panel of experts in hematologic malignancies discusses maintenance strategies for mantle cell lymphoma with particular emphasis on treatment considerations related to the COVID-19 pandemic and real-world data.
Factors for Consideration in Treatment Decision-making for MCL
Focusing on the differences in treatment considerations between younger and older patients, Michael Wang, MD, discusses the current treatment landscape in mantle cell lymphoma.
Disease Overview: Mantle Cell Lymphoma
Anthony R. Mato, MD, MSCE, introduces the panel, and Alexey V. Danilov, MD, PhD, provides an overview of the incidence, presentation, pathologic features, and treatment landscape for mantle cell lymphoma.
Dr. Davids on the Future of CAR T-Cell Therapy in CLL
Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.
Dr. Davids on Investigational Doublets and Triplets in CLL
Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.
Dr. Davids on Selecting Between Continuous and Time-Limited Therapy in CLL
Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.
Dr. Davids on Factors to Inform Treatment Selection in CLL
Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.
Dr. Davids on the Use of Chemoimmunotherapy in CLL
Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Dr. Davids on Remaining Questions With Umbralisib/Ibrutinib in CLL and MCL
Matthew S. Davids, MD, MMSc, discusses remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.
Dr. Davids on Updated Data With Ibrutinib/Umbralisib in R/R CLL and MCL
Matthew S. Davids, MD, MMSc, discusses updated findings from a phase 1/1b study which examined the combination of ibrutinib (Imbruvica) and umbralisib in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Dr. Davids on Rationale for Ibrutinib/Umbralisib Combo in R/R CLL and MCL
Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.
Dr. Davids on Exciting Data With Acalabrutinib in CLL
Matthew S. Davids, MD, MMSc, director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses exciting data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).
Dr. Davids on Cost Effectiveness of Time-Limited Therapy With Venetoclax/Obinutuzumab in CLL
Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the potential cost effectiveness of a 12-month fixed duration of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) in first-line chronic lymphocytic leukemia (CLL).
Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma
Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL
2 Clarke Drive Cranbury, NJ 08512